Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biogena Group Invest AGWBO:BIO 59 3-Year RORE % is 44.29 as of Jan. 2026. GuruFocus rates WBO:BIO with a GF Score™ of 59/100 and a GF Value™ of €3.49 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,827 Consumer Packaged Goods companies, Biogena Group Invest AG ranks better than 77.67% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Biogena Group Invest AG's 3-Year RORE % for the quarter that ended in Jan. 2026 was 44.29%.
The industry rank for Biogena Group Invest AG's 3-Year RORE % or its related term are showing as below:
WBO:BIO's 3-Year RORE % is ranked better than 77.67% of 1827
companies
in the Consumer Packaged Goods industry
Industry Median: 6.03
vs WBO:BIO: 44.29
Biogena Group Invest AG (WBO:BIO) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Biogena Group Invest AG 3-Year RORE % Related Terms
Biogena Group Invest AG 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:BIO vs KHC, GIS, HRL: 3-Year RORE % Comparison
For the Packaged Foods subindustry, Biogena Group Invest AG's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogena Group Invest AG 3-Year RORE % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Biogena Group Invest AG's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Biogena Group Invest AG's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jan. 2026 and 3-year before.
Biogena Group Invest AG (WBO:BIO) has a 3-Year RORE % of 44.29 as of Jan. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Biogena Group Invest AG and its competitors. According to the industry distribution chart, Biogena Group Invest AG ranks #408 out of 1827 companies in the Consumer Packaged Goods industry, placing it in the top 22.3%.
Is Biogena Group Invest AG's 3-Year RORE % too high?
Biogena Group Invest AG's current 3-Year RORE % is 44.29. The Consumer Packaged Goods industry median 3-Year RORE % is 6.03. Biogena Group Invest AG's value of 44.29 is 634.5% above this industry median. Based on the distribution chart, Biogena Group Invest AG ranks #408 out of 1827 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Biogena Group Invest AG has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogena Group Invest AG's 3-Year RORE % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Biogena Group Invest AG ranks #408 out of 1827 companies for 3-Year RORE %. This places Biogena Group Invest AG in the top 22% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 6.03. Biogena Group Invest AG's value of 44.29 is 634.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Consumer Packaged Goods company?
The median 3-Year RORE % among Consumer Packaged Goods companies is 6.03, based on 1,827 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogena Group Invest AG's current 3-Year RORE % of 44.29 is 634.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Biogena Group Invest AG and its competitors. For the Consumer Packaged Goods industry, the median 3-Year RORE % is 6.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogena Group Invest AG's current 3-Year RORE % is 44.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogena Group Invest AG stock overvalued right now?
Based on GuruFocus' analysis, Biogena Group Invest AG (WBO:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.49, compared to a current price of €5.30 — trading 51.9% above its estimated fair value. The current 3-Year RORE % is 44.29 and 634.5% above the Consumer Packaged Goods industry median of 6.03. Biogena Group Invest AG's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Biogena Group Invest AG (WBO:BIO), the current 3-Year RORE % is 44.29 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogena Group Invest AG (WBO:BIO) Overvalued in 2026?
Based on GuruFocus' analysis, Biogena Group Invest AG stock appears to be overvalued.
The current stock price of €5.30 is trading 51.9% above its estimated GF Value™ of €3.49.
GuruFocus considers Biogena Group Invest AG to be Significantly Overvalued.
Key valuation signals for WBO:BIO:
3-Year RORE %: 44.29
GF Value™: €3.49 vs. price of €5.30 (51.9% above fair value)
Industry Position: 634.5% above the Consumer Packaged Goods median (#408 of 1827)
No single metric tells the full story. See the WBO:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogena Group Invest AG is a holding company. It is engaged in the development and distribution of products and services in the field of health and nutrition. In particular, the focus is on iron, mineral and osteoporosis product innovations and new integrated solutions in the area of workplace health promotion. Its products include vitamin, mineral, enzymes, medicinal mushrooms, among others.
59GF Score
Get the complete analysis for WBO:BIO
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:BIO has been successfully added to your 
